AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-3. (canceled).

4. (currently amended): ~~The mutual salt of claim 1~~A crystalline hydrate of raloxifene bisphosphonate, which is selected from the group consisting of crystalline 5/2hydrate of raloxifene 1/2etidronate ~~5/2hydrate,~~, crystalline trihydrate of raloxifene pamidronate, crystalline pentahydrate of ~~trihydrate,~~ raloxifene alendronate, crystalline trihydrate of ~~pentahydrate,~~ raloxifene risedronate ~~trihydrate,~~, crystalline monohydrate of raloxifene incadronate ~~monohydrate, or~~and crystalline tetrahydrate of raloxifene zoledronate ~~tetrahydrate~~.

5. (currently amended): The ~~mutual salt of claim 1~~crystalline hydrate of claim 4, which is crystalline pentahydrate of raloxifene alendronate ~~pentahydrate~~.

6. (currently amended): The ~~mutual salt~~crystalline hydrate of claim 5, whose powder X-ray diffraction spectrum ($I/I_0 \geq 20$) shows at 2θ values of 4.2±0.2, 8.4±0.2, 9.4±0.2, 9.7±0.2, 10.8±0.2, 13.3±0.2, 13.8±0.2, 14.2±0.2, 16.7±0.2, 18.3±0.2, 18.6±0.2, 19.4±0.2, 19.8±0.2, 20.5±0.2, 20.8±0.2, 21.2±0.2, 21.6±0.2, 25.5±0.2 and 26.9±0.2.

7. (currently amended): The ~~mutual salt~~crystalline hydrate of claim ~~1~~4, which is crystalline trihydrate of raloxifene risedronate ~~trihydrate~~.

8. (currently amended): The ~~mutual salt~~crystalline hydrate of claim 7, whose powder X-ray diffraction spectrum ($I/I_0 \geq 20$) shows at 2θ values of 6.8±0.2, 10.3±0.2, 12.3±0.2, 15.2±0.2, 16.5±0.2, 17.0±0.2, 17.3±0.2, 17.7±0.2, 20.3±0.2, 20.9±0.2, 21.2±0.2, 19.4±0.2, 19.8±0.2, 20.5±0.2, 20.8±0.2, 21.2±0.2, 21.6±0.2, 25.5±0.2 and 26.9±0.2.

9. (currently amended): A process for preparing ~~a mutual salt of~~ the crystalline hydrate of raloxifene ~~and bisphosphonic acid of formula (I)~~bisphosphonate of claim 4, which comprises the step of reacting a ~~compound of formula (II)~~raloxifene free base or its solvate with a ~~compound of formula (III) or its solvate, in a solvent:~~



~~(II)~~



~~(III)~~

~~wherein R_1 and R_2 have the same meanings as defined in claim 1~~bisphosphonic acid selected from the group consisting of etidronic acid, pamidronic acid, alendronic acid, risedronic acid, incadronic acid and zoledronic acid, or its solvate, in a solvent.

10. (currently amended): The ~~precess~~process of claim 9, wherein the solvent is selected from the group consisting of water, methanol, ethanol, propanol, isopropanol, acetone, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and a mixture thereof.

11. (currently amended): A pharmaceutical composition for preventing and treating osteoporosis comprising ~~the mutual salt of formula (I)~~the crystalline hydrate of raloxifene bisphosphonate of claim 4 as an active ingredient together with pharmaceutically acceptable carriers~~:~~



~~(I)~~

~~wherein R_1, R_2, R_3, R_4, x and y have the same meanings as defined in claim 1~~.

12. (currently amended): A pharmaceutical composition for preventing and treating hypercalcemia comprising the ~~mutual salt of formula (I)~~crystalline hydrate of raloxifene bisphosphonate of claim 4 as an active ingredient together with pharmaceutically acceptable carriers~~:~~



~~(I)~~

~~wherein R_1, R_2, R_3, R_4, x and y have the same meanings as defined in claim 1~~.

13. (currently amended): A pharmaceutical composition for preventing and treating hyperlipidemia comprising the ~~mutual salt of formula (I)~~crystalline hydrate of raloxifene bisphosphonate of claim 4 as an active ingredient together with pharmaceutically acceptable carriers~~:~~



~~(I)~~

~~wherein R_1, R_2, R_3, R_4, x and y have the same meanings as defined in claim 1~~.